首页 › 基金 › Paradigm Biocapital Advisors LP › VRDN

Paradigm Biocapital Advisors LP 对 VRDN 的持仓历史

VIRIDIAN THERAPEUTICS INC · 医疗保健

Paradigm Biocapital Advisors LP 在 Q3 2026 的 13F 申报中披露持有 VRDN(VIRIDIAN THERAPEUTICS INC)12,412,886 股,市值约 US$227.1M,约占其申报组合的 4.52%,在其申报持仓中市值排名第 6 位。 Paradigm Biocapital Advisors LP 最近 13 个申报季度中有 13 个季度披露了 VRDN 持仓,最早可追溯至 Q3 2023。

最新持仓 (Q3 2026)12.41M 股
申报持仓市值$227.08M
组合权重4.52%
首次申报Q3 2023
最近变动增持
更新于2026-11-16

最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR

Paradigm Biocapital Advisors LP 对 VRDN 的持仓演变

Paradigm Biocapital Advisors LP 于 Q3 2023 首次披露 VRDN 持仓:3,681,747 股(约 US$56.5M)。 该持仓在 Q3 2026 达到峰值 12,412,886 股,市值约 US$227.1M。 在 13 次申报中,Paradigm Biocapital Advisors LP 7 次增持、4 次减持、1 次保持不变。 最近一期申报(Q3 2026)显示持股 12,412,886 股、市值约 US$227.1M,环比增持 5,689,098 股。。 持仓曾出现大幅变动:Q1 2026 增持约 118% (随后一个季度股价下跌 6%)、Q2 2026 增持约 114% (随后一个季度股价上涨 12%)、Q3 2026 增持约 85% (随后一个季度股价上涨 50%)。

逐季持仓明细

季度股数金额变化
Q3 2023 3.68M $56.48M 新进
Q4 2023 4.79M $104.42M 增持
Q1 2024 5.03M $88.10M 增持
Q2 2024 2.90M $37.68M 减持
Q3 2024 2.90M $65.88M 持有
Q4 2024 1.82M $34.89M 减持
Q1 2025 2.10M $28.24M 增持
Q2 2025 2.74M $38.33M 增持
Q3 2025 2.61M $56.31M 减持
Q4 2025 1.44M $44.91M 减持
Q1 2026 3.15M $61.59M 增持
Q2 2026 6.72M $123.52M 增持
Q3 2026 12.41M $227.08M 增持

折线上的点按变动类型着色;缺失季度表示该季未申报持仓。

关于 VRDN 与 13F 数据

VRDN(VIRIDIAN THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 42 只申报持有 VRDN,申报仓位最大的包括:Kynam Capital Management, LP (US$126.6M), Bellevue Group AG (US$123.7M), RTW INVESTMENTS, LP (US$102.0M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 VRDN 的基金

查看 VRDN 的全部基金持有人 →

常见问题

How long has Paradigm Biocapital Advisors LP held VRDN?

Paradigm Biocapital Advisors LP has disclosed VRDN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Paradigm Biocapital Advisors LP's current position in VRDN?

As of Q3 2026, Paradigm Biocapital Advisors LP holds 12.41M shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $227.08M, representing 4.52% of its reported portfolio and ranking #6.

Has Paradigm Biocapital Advisors LP been buying or selling VRDN?

In the latest 13F filing (Q3 2026), Paradigm Biocapital Advisors LP increased its position in VRDN. The position peaked in Q3 2026 at 12.41M shares.

Which other funds hold VRDN?

Other major institutional holders of VRDN include Kynam Capital Management, LP, Bellevue Group AG, RTW INVESTMENTS, LP, among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.